Journal Mobile Options
Table of Contents
Vol. 34, No. 4, 2011
Issue release date: October 2011
Am J Nephrol 2011;34:298–308

Association of Mean Weekly Epoetin Alfa Dose with Mortality Risk in a Retrospective Cohort Study of Medicare Hemodialysis Patients

Weinhandl E.D. · Gilbertson D.T. · Collins A.J.
aChronic Disease Research Group, Minneapolis Medical Research Foundation, and bDepartment of Medicine, University of Minnesota, Minneapolis, Minn., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background/Aims: Randomized trials of hemoglobin targeting in chronic kidney disease suggest that erythropoiesis-stimulating agent (ESA) dosing increases mortality risk, but dosing intensity is confounded by hemoglobin concentration. Appropriately designed observational studies are needed to clarify the association of ESA dosing with mortality risk. Methods: Using Medicare claims, we conducted a retrospective cohort study of mortality risk associated with epoetin alfa (EPO) dosing in prevalent hemodialysis patients (n = 137,918), 2000–2004. We used marginal structural modeling to account for time-varying confounding attributable to recent history of blood transfusion and catheter insertion for vascular access, hemoglobin, hospital admission and days, and intravenous iron dosing. We stratified mortality analyses according to hemoglobin level (<10, 10–10.9, 11–11.9, and ≧12 g/dl). Results: With adjustment for serial correlation in EPO dosing, hemoglobin, hospital admission and days, and intravenous iron administration were the strongest predictors of outpatient EPO dosing. With hemoglobin <10 g/dl, mean weekly EPO dose in a 3-month period was negatively associated with subsequent mortality risk. With hemoglobin 10–10.9 and 11–11.9 g/dl, EPO dose and mortality risk were associated in a U-shaped form. With hemoglobin ≧12 g/dl, mean weekly EPO dose >20,000 IU was positively associated with mortality risk. Conclusions: ESA dosing may be directly associated with risk of death, but the nature of the association likely varies according to hemoglobin concentration. Small doses with hemoglobin ≤12 g/dl and large doses with hemoglobin ≧10 g/dl may both be associated with poor outcomes.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Besarab A, Bolton WK, Browne JK, et al: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584–590.
  2. Singh AK, Szczech L, Tang KL, et al: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085–2098.
  3. Drueke TB, Locatelli F, Clyne N, et al: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071–2084.
  4. Pfeffer MA, Burdmann EA, Chen CY, et al: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019–2032.
  5. Zhang Y, Thamer M, Stefanik K, et al: Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 2004;44:866–876.
  6. Bradbury BD, Wang O, Critchlow CW, et al: Exploring relative mortality and epoetin alfa dose among hemodialysis patients. Am J Kidney Dis 2008;51:62–70.
  7. Szczech LA, Barnhart HX, Inrig JK, et al: Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes. Kidney Int 2008;74:791–798.
  8. Zhang Y, Thamer M, Cotter D, et al: Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States. Clin J Am Soc Nephrol 2009;4:638–644.
  9. Bradbury BD, Do TP, Winkelmayer WC, et al: Greater epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dl. Pharmacoepidemiol Drug Saf 2009;18:932–940.
  10. Wang O, Kilpatrick RD, Critchlow CW, et al: Relationship between epoetin alfa dose and mortality: findings from a marginal structural model. Clin J Am Soc Nephrol 2010;5:182–188.
  11. Adamson JW: Hyporesponsiveness to erythropoiesis-stimulating agents in chronic kidney disease: the many faces of inflammation. Adv Chronic Kidney Dis 2009;16:76–82.

    External Resources

  12. Robins JM, Hernan MA, Brumback B: Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550–560.
  13. Petersen ML, Deeks SG, Martin JN, van der Laan MJ: History-adjusted marginal structural models for estimating time-varying effect modification. Am J Epidemiol 2007;166:985–993.

    External Resources

  14. Nagelkerke NJD: A note on a general definition of the coefficient of determination. Biometrika 1991;78:691–692.

    External Resources

  15. Phrommintikul A, Haas SJ, Elsik M, Krum H: Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007;369:381–388.
  16. Fishbane S, Besarab A: Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol 2007;2:1274–1282.
  17. Regidor DL, Kopple JD, Kovesdy CP, et al: Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006;17:1181–1191.
  18. Robinson BM, Joffe MM, Berns JS, et al: Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. Kidney Int 2005;68:2323–2330.
  19. Brines M, Cerami A: Discovering erythropoietin’s extra-hematopoietic functions: biology and clinical promise. Kidney Int 2006;70:246–250.
  20. Weiner DE, Miskulin DC, Seefeld K, et al: Reducing versus discontinuing erythropoietin at high hemoglobin levels. J Am Soc Nephrol 2007;18:3184–3191.
  21. Acquavella JF, Weinhandl E, Bradbury BD, et al: Confounding by indication studying epoetin and mortality (abstract). Pharmacoepidemiol Drug Saf 2009;18(suppl 1):S28.

    External Resources

  22. Brookhart MA, Schneeweiss S, Avorn J, et al: Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA 2010;303:857–864.
  23. Keown PA, Churchill DN, Poulin-Costello M, et al: Dialysis patients treated with epoetin alfa show improved anemia symptoms: a new analysis of the Canadian Erythropoietin Study Group trial. Hemodial Int 2010;14:168–173.

    External Resources

  24. Muirhead N, Keown PA, Churchill DN, et al: Dialysis patients treated with epoetin α show improved exercise tolerance and physical function: a new analysis of the Canadian Erythropoietin Study Group trial. Hemodial Int 2010 (E-pub ahead of print).
  25. Tsai YC, Hung CC, Hwang SJ, et al: Quality of life predicts risks of end-stage renal disease and mortality in patients with chronic kidney disease. Nephrol Dial Transplant 2010;25:1621–1626.

    External Resources

  26. Ibrahim HN, Skeans, MA, Li Q, Ishani A, Snyder JJ: Blood transfusions in kidney transplant candidates are common and associated with adverse outcomes. Clin Transplant (E-pub ahead of print).
  27. Unger EF, Thompson AM, Blank MJ, Temple R: Erythropoiesis-stimulating agents –time for a reevaluation. N Engl J Med 2010;362:189–192.
  28. Strippoli GF: Effects of the dose of erythropoiesis-stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol. Trials 2010;11:70.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50